Gain Therapeutics Announces Poster Presentation at AD/PD™ 2025 International Conference on Latest Research in Parkinson’s Disease
Bethesda, MD, March 28, 2025 – Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in the discovery and development of allosteric small molecule therapies, is excited to announce that a poster detailing the design of the Phase 1b clinical trial of GT-02287 for the treatment of Parkinson’s disease will be presented at the prestigious AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders. The conference is being held from April 1-5, 2025, in Vienna, Austria.
About Gain Therapeutics and GT-02287
Gain Therapeutics is dedicated to revolutionizing the way diseases are treated by targeting allosteric sites on proteins. GT-02287 is a first-in-class, orally administered, allosteric small molecule therapy that selectively targets the LRRK2 kinase, which is implicated in Parkinson’s disease. The company’s unique approach to drug development focuses on modifying the behavior of disease-causing proteins, rather than targeting their removal or replacement.
Phase 1b Clinical Trial Design
The Phase 1b clinical trial of GT-02287 aims to evaluate the safety, tolerability, and pharmacokinetics of the drug in patients with Parkinson’s disease. The randomized, double-blind, placebo-controlled study will include approximately 40 participants. Participants will be randomly assigned to receive either GT-02287 or a placebo for 14 days. The primary outcome measures will be assessed through safety monitoring, clinical laboratory evaluations, and pharmacokinetic analysis.
Impact on Individuals with Parkinson’s Disease
Parkinson’s disease is a progressive neurodegenerative disorder that affects approximately 10 million people worldwide. Currently, there are no disease-modifying treatments available, and the current standard of care focuses on managing symptoms through medication. GT-02287 represents a potential game-changer in the treatment landscape for Parkinson’s disease. The results of the Phase 1b clinical trial could provide valuable insights into the safety and efficacy of this novel therapy, offering hope to the millions of individuals and their families affected by this debilitating condition.
Global Implications
The potential impact of Gain Therapeutics’ research on the global healthcare landscape is significant. If successful, GT-02287 could represent the first disease-modifying therapy for Parkinson’s disease. This breakthrough could lead to a paradigm shift in the way we approach the treatment of neurodegenerative disorders, paving the way for the development of similar therapies for other conditions such as Alzheimer’s disease, Huntington’s disease, and others.
Conclusion
Gain Therapeutics’ announcement of a poster presentation at the AD/PD™ 2025 International Conference on the design of the Phase 1b clinical trial for GT-02287 in Parkinson’s disease marks an important milestone in the development of this innovative therapy. The potential impact on individuals with Parkinson’s disease, as well as the global healthcare community, is significant. The results of this study could provide valuable insights into the safety and efficacy of GT-02287, offering hope to millions of individuals and their families affected by this debilitating condition. Stay tuned for further updates on this groundbreaking research.
- Gain Therapeutics to present poster on GT-02287 at AD/PD™ 2025 International Conference
- Phase 1b clinical trial evaluates safety, tolerability, and pharmacokinetics of GT-02287 in Parkinson’s disease
- GT-02287 represents a potential game-changer in the treatment landscape for Parkinson’s disease
- Results could pave the way for the development of similar therapies for other neurodegenerative disorders
